A systematic review comparing cisplatin and carboplatin plus paclitaxel-based chemotherapy for recurrent or metastatic cervical cancer.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Gynecologic Oncology

• Publication date

  2014-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ygyno.2014.01.042PMID 24486604
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-Line Paclitaxel and Carboplatin in Persistent/Recurrent or Advanced Cervical Cancer: A Retrospective Analysis of Patients Treated at Brazilian National Cancer Institute

  2013cited by this paper
• Evaluation of paclitaxel/carboplatin in a dose dense or weekly regimen in 66 patients with recurrent or primary metastatic cervical cancer.

  2012cited by this paper
• A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505).

  2012influential reference
• Ifosfamide, paclitaxel, and carboplatin, a novel triplet regimen for advanced, recurrent, or persistent carcinoma of the cervix: a phase II trial.

  2011cited by this paper
• The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy.

  2009cited by this paper
• Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer

  2009cited by this paper
• Randomized multicenter phase II trial of cisplatin and ifosfamide with or without paclitaxel in recurrent or metastatic carcinoma of the uterine cervix: a Hellenic Cooperative Oncology Group (HeCOG) study.

  2009cited by this paper
• Carboplatin and Paclitaxel in Metastatic or Recurrent Cervical Cancer

  2009cited by this paper
• Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study.

  2009influential reference
• Chemotherapy for recurrent cervical cancer.

  2007cited by this paper
• Cancer Statistics, 2007

  2007cited by this paper
• A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.

  2007cited by this paper
• Salvage chemotherapy with a combination of paclitaxel, ifosfamide, and cisplatin for the patients with recurrent carcinoma of the uterine cervix

  2005cited by this paper
• Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience.

  2005cited by this paper
• Chemotherapy for Recurrent or Persistent Cervical Cancer

  2004cited by this paper
• Paclitaxel and Carboplatin for Recurrent or Persistent Cancer of the Cervix

  2004cited by this paper
• Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study.

  2004cited by this paper
• Phase II trial of paclitaxel (T) and carboplatin (C) in patients with recurrent or metastatic cervical carcinoma

  2004cited by this paper
• Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

  2003cited by this paper
• Combination of ifosfamide, paclitaxel, and cisplatin for the treatment of metastatic and recurrent carcinoma of the uterine cervix: a phase II study of the Hellenic Cooperative Oncology Group.

  2002cited by this paper
• Phase II trial of paclitaxel and cisplatin in metastatic and recurrent carcinoma of the uterine cervix.

  1999cited by this paper
• Paclitaxel, ifosfamide and cisplatin (TIP) chemotherapy for recurrent or persistent squamous-cell cervical cancer.

  1999cited by this paper
• Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: a surgicopathologic study.

  1999cited by this paper
• Paclitaxel and cisplatin as first-line therapy in recurrent or advanced squamous cell carcinoma of the cervix: a gynecologic oncology group study.

  1999cited by this paper
• Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

  1997cited by this paper
• A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study.

  1989cited by this paper
• Meta-analysis in clinical trials.

  1986cited by this paper
• Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: a Gynecologic Oncology Group study.

  1985cited by this paper
• Statistical guidelines for contributors to medical journals.

  1983cited by this paper
• cis-Dichlorodiammineplatinum(II) in the treatment of gynecologic malignancies: phase II trials by the Gynecologic Oncology Group.

  1979cited by this paper

• Dysregulated Circular RNA and Long non-coding RNA-Mediated Regulatory Competing Endogenous RNA Networks (ceRNETs) in Ovarian and Cervical Cancers: A Non-coding RNA-Mediated Mechanism of Chemotherapeutic Resistance with New Emerging Clinical Capacities.

  2025cites this paper
• Multitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain

  2025cites this paper
• From CAR-T Cells to Exosome-Based Immunotherapy: Exploring the Frontiers of Cell-Free Targeted Cancer Therapeutics

  2025cites this paper
• Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers

  2025cites this paper
• Cervical Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology.

  2025cites this paper
• The Molecular Mechanism for Reversing Chemotherapy Drug Resistance in Cervical Cancer

  2025cites this paper
• TFF3 sensitizes cervical carcinoma cells to cisplatin toxicity by binding to IGF2R

  2025cites this paper
• Retinoic Acid-Induced Transglutaminase 2 Expression Reduces Sensitivity to Cisplatin in the Hormone-Positive MCF-7 Breast Cancer Cell Model

  2025cites this paper
• Recent advances in antitumor Pt(IV) complexes: Dual targeting and chemoimmunotherapy

  2025cites this paper
• Investigating Cisplatin Resistance in Squamous Cervical Cancer: Proteomic Insights into DNA Repair Pathways and Omics-Based Drug Repurposing.

  2025cites this paper
• Long noncoding RNA UCA1 knockdown inhibits cisplatin-resistant cervical cancer tumorigenesis via the miR-195-5p/IKBKB axis

  2025cites this paper
• Small T Oncoprotein of Merkel Cell Polyomavirus Attenuates Cisplatin-Induced Apoptosis and Enhances E1, E6/E7, MMP-1, and Ki-67 Expression in HeLa Cervical Cancer Cells

  2025cites this paper
• Chrysin Exhibits Selective Antiproliferative and Antimigratory Activities in a Wide Range of Human-derived Cervical Cancer Cell Lines.

  2025cites this paper
• Author's reply to: Cisplatin versus carboplatin?

  2025cites this paper
• Vulvar Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology.

  2024cites this paper
• Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study

  2024cites this paper
• Overexpression of HYOU1 is associated with cisplatin resistance and may depend on m6A modification in patients with cervical cancer

  2024cites this paper
• Targeting CDCP1 boost CD8+ T cells-mediated cytotoxicity in cervical cancer via the JAK/STAT signaling pathway

  2024cites this paper
• Opportunities to advance cervical cancer prevention and care

  2024cites this paper
• RecQ protein‐like 4 drives cisplatin chemosensitivity of cervical cancer cells by modulating annexin A2

  2024cites this paper
• A distinct subset of urothelial cells with enhanced EMT features promotes chemotherapy resistance and cancer recurrence by increasing COL4A1-ITGB1 mediated angiogenesis.

  2024cites this paper
• Resveratrol in the Treatment of Gynecological Cancer: Mechanisms and Therapeutic Potential.

  2024cites this paper
• Fertility-sparing treatment in cancer patients: how can we help in the 21st century?

  2024cites this paper
• Inhibition of CD73 expression or A2AR blockade reduces MRP1 expression and increases the sensitivity of cervical cancer cells to cisplatin

  2023influential citation
• Targeting CDCP1 to Amplify CD8⁺ T cell Cytotoxicity via JAK/STAT Signaling in Cervical Cancer

  2023cites this paper
• Imaging of cervical cancer. Consensus of experts

  2023cites this paper
• The potential of PCNA inhibition as a therapeutic strategy in cervical cancer

  2023cites this paper
• New insights into the interaction between m6A modification and lncRNA in cancer drug resistance

  2023cites this paper
• Non-thermal Acoustic Enhancement of Chemotherapeutic Effects of Cisplatin on Xenografted Cervical Cancer in Mice

  2023cites this paper
• It Is All about Probiotics to Control Cervical Cancer

  2023cites this paper
• Recommendations for Cost-Conscious Treatment of Basal Cell Carcinoma

  2023cites this paper
• Downregulation of VPS13C promotes cisplatin resistance in cervical cancer by upregulating GSTP1

  2023cites this paper
• Design of a Synthetic Long Peptide Vaccine Targeting HPV-16 and -18 Using Immunoinformatic Methods

  2023cites this paper
• Circular RNA ARHGAP5 inhibits cisplatin resistance in cervical squamous cell carcinoma by interacting with AUF1

  2023cites this paper
• Definitive vs palliative pelvic radiation for patients with newly diagnosed stage IVB cervical cancer treated with bevacizumab – An exploratory study

  2022cites this paper
• Resveratrol against Cervical Cancer: Evidence from In Vitro and In Vivo Studies

  2022cites this paper
• Acute and long-term toxicity in patients undergoing induction chemotherapy followed by thermoradiotherapy for advanced cervical cancer

  2022cites this paper
• Cervical cancer heterogeneity: a constant battle against viruses and drugs

  2022influential citation
• Pllans–II Induces Cell Death in Cervical Cancer Squamous Epithelial Cells via Unfolded Protein Accumulation and Endoplasmic Reticulum Stress

  2022cites this paper
• Insights of ethyl acetate fraction from Vassobia breviflora in multidrug-resistant bacteria and cancer cells: from biological to therapeutic

  2022cites this paper
• Dickkopf‐1 expression is repressed by oncogenic human papillomaviruses (HPVs) and regulates the Cisplatin sensitivity of HPV‐positive cancer cells in a JNK‐dependent manner

  2022cites this paper
• Is There a Place for Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer?

  2022cites this paper
• Small Cell (Neuroendocrine) Carcinoma of the Cervix: An Analysis for 19 Cases and Literature Review

  2022cites this paper
• Cellular landscaping of cisplatin resistance in cervical cancer.

  2022cites this paper
• Curcumenol Targeting YWHAG Inhibits the Pentose Phosphate Pathway and Enhances Antitumor Effects of Cisplatin

  2022cites this paper
• Paclitaxel-carboplatin and bevacizumab combination with maintenance bevacizumab therapy for metastatic, recurrent, and persistent uterine cervical cancer: An open-label multicenter phase II trial (JGOG1079).

  2022cites this paper
• Phenethylisothiocyanate Potentiates Platinum Therapy by Reversing Cisplatin Resistance in Cervical Cancer

  2022cites this paper
• Cisplatin Nanoparticles Promote Intratumoral CD8+ T Cell Priming via Antigen Presentation and T Cell Receptor Crosstalk.

  2022cites this paper
• CD44 Receptor-Mediated/Reactive Oxygen Species-Sensitive Delivery of Nanophotosensitizers against Cervical Cancer Cells

  2022cites this paper
• Discovery of pyrimidine-bridged CA-4 CBSIs for the treatment of cervical cancer in combination with cisplatin with significantly reduced nephrotoxicity.

  2022cites this paper
• Overexpression of Secreted Phosphoprotein 1 (SPP1) predicts poor survival in HPV positive cervical cancer.

  2022cites this paper
• Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 2 with Recommendations on Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities.

  2022cites this paper
• Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) - Part 1 with Recommendations on Epidemiology, Screening, Diagnostics and Therapy.

  2022cites this paper
• Matrine exerts antitumor activity in cervical cancer by protective autophagy via the Akt/mTOR pathway in vitro and in vivo

  2022cites this paper
• Neoadjuvant Chemotherapy Prior Fertility-Sparing Surgery in Women with FIGO 2018 Stage IB2 Cervical Cancer: A Systematic Review

  2022cites this paper
• Cisplatin plus paclitaxel and bevacizumab versus carboplatin plus paclitaxel and bevacizumab for the first-line treatment of metastatic or recurrent cervical cancer

  2022cites this paper
• Efficacy and Safety of Immunotherapy for Cervical Cancer—A Systematic Review of Clinical Trials

  2022cites this paper
• MicroRNA-92a-3p Enhances Cisplatin Resistance by Regulating Krüppel-Like Factor 4-Mediated Cell Apoptosis and Epithelial-to-Mesenchymal Transition in Cervical Cancer

  2022cites this paper
• Targeted drug delivery in cervical cancer: Current perspectives.

  2022cites this paper
• Dendritic cells loaded with exosomes derived from cancer stem cell‐enriched spheroids as a potential immunotherapeutic option

  2021cites this paper
• Structure-activity insights of harmine targeting DNA, ROS inducing cytotoxicity with PARP mediated apoptosis against cervical cancer, anti-biofilm formation and in vivo therapeutic study

  2021cites this paper
• Clinical guidelines for diagnosis, treatment and monitoring of patients with cervical cancer

  2021cites this paper
• Integral membrane protein 2A enhances sensitivity to chemotherapy via notch signaling pathway in cervical cancer

  2021cites this paper
• Novel Antigenic Targets of HPV Therapeutic Vaccines

  2021cites this paper
• Zinc organocomplexes containing non-steroid anti-inflammatories and plane aromatic diimines: New potential drugs

  2021cites this paper
• Constructing a Novel Signature Based on Immune-Related lncRNA to Improve Prognosis Prediction of Cervical Squamous Cell Carcinoma Patients

  2021cites this paper
• Diagnostic and Therapeutic Approach in a Metastatic Vaginal Adenocarcinoma: A Case Report

  2021cites this paper
• Neoadjuvant chemotherapy combined with radical surgery for stage IB2/IIA2 cervical squamous cell carcinoma: a prospective, randomized controlled study of 35 patients

  2021cites this paper
• Potent Therapeutic Efficacy of a Novel HPV16E7-HBcAg-Hsp65 Fusion Protein Vaccine

  2021cites this paper
• Overview of Evidence-Based Chemotherapy for Oral Cancer: Focus on Drug Resistance Related to the Epithelial-Mesenchymal Transition

  2021influential citation
• Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives.

  2021cites this paper
• Nanobiotechnology in animal production and health

  2021cites this paper
• Nanoparticle-based drug delivery systems with platinum drugs for overcoming cancer drug resistance.

  2021cites this paper
• Molecular and Cellular Mechanisms of Metformin in Cervical Cancer

  2021cites this paper
• Adding aprepitant to palonosetron does not decrease carboplatin-induced nausea and vomiting in patients with gynecologic cancer

  2021cites this paper
• Inhibition of the notch signaling pathway overcomes resistance of cervical cancer cells to paclitaxel through retardation of the epithelial–mesenchymal transition process

  2021cites this paper
• Therapeutic options for the management of cervical cancer

  2021cites this paper
• Potential of miRNAs in cervical cancer chemoresistance

  2021cites this paper
• Co-expression of SOX2 and HR-HPV RISH predicts poor prognosis in small cell neuroendocrine carcinoma of the uterine cervix

  2021cites this paper
• Neoadjuvant chemotherapy in early-stage cervical cancer (<2 cm) before conization for fertility preservation: is there any advantage over upfront conization?

  2021cites this paper
• Postoperative Adjuvant Chemotherapy in Locally Advanced Cervical Cancer Patients with Optimal Response to Neoadjuvant Chemotherapy: A Retrospective Study

  2020cites this paper
• Anticancerous effect of rutin against HPV- C33A cervical cancer cells via G0/G1 cell cycle arrest and apoptotic induction.

  2020cites this paper
• CRISPR/Cas9-mediated knockout of MLL5 enhances apoptotic effect of cisplatin in HeLa cells in vitro

  2020cites this paper
• Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer

  2020cites this paper
• Strong vaccine responses during chemotherapy are associated with prolonged cancer survival

  2020cites this paper
• Therapie des lokal fortgeschrittenen, rezidivierten oder metastasierten Zervixkarzinoms

  2020cites this paper
• Selective photodynamic effects on cervical cancer cells provided by P123 Pluronic®-based nanoparticles modulating hypericin delivery.

  2020cites this paper
• CRISPR-mediated knockdown of miR-214 modulates cell fate in response to anti-cancer drugs in HPV-negative and HPV-positive cervical cancer cells

  2020cites this paper
• British Gynaecological Cancer Society (BGCS) vulval cancer guidelines: Recommendations for practice.

  2020cites this paper
• Colloidal Nanocarriers a Versatile Targeted Delivery System for Cervical Cancer.

  2020cites this paper
• The Phytochemical Indicaxanthin Synergistically Enhances Cisplatin-Induced Apoptosis in HeLa Cells via Oxidative Stress-Dependent p53/p21waf1 Axis

  2020cites this paper
• Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer

  2020cites this paper
• PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review

  2020cites this paper
• HP1γ Sensitizes Cervical Cancer Cells to Cisplatin through the Suppression of UBE2L3

  2020cites this paper
• Neoadjuvant chemotherapy, radical hysterectomy and chemoradiation for stage iva cervical carcinoma

  2020cites this paper
• Recurrent cervical cancer treated with palliative chemotherapy: real-world outcome

  2020cites this paper
• Molecular-guided therapy for disseminated cervical cancer: present and future

  2020cites this paper
• HPV post-infection microenvironment and cervical cancer.

  2020cites this paper
• British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice.

  2020cites this paper
• Avanços na quimioterapia do câncer ginecológico: uma revisão

  2020cites this paper